Table 2.

Comparison of percentages of GPs reporting to deprescribe medication in the case of a frail 82-year-old patient without and with history of cardiovascular disease (CVD) and most frequently mentioned reasons to deprescribe for the case

	History of CVD				p-value1
	No		Yes
Medication	Percentage of GPs (95% CI)	Reasons to deprescribe (frequency)	Percentage of GPs (95% CI)	Reasons to deprescribe (frequency)
Atorvastatin 40 mg	100%	- Not enough benefit (56) - No indication (35) - No evidence (16) - Short estimated life expectancy (16)	76% (69–83%)	- Not enough benefit (30) - Other (25) - Short estimated life expectancy (19)	< 0.001
Pantoprazole 20 mg	88% (83–93%)	- No indication (111) - In reserve, no long-term therapy (6) - Not enough benefit (5)	81% (75–87%)	- No indication (90) - Not enough benefit (7)	0.002
Aspirin 100 mg	74% (67–81%)	- No indication (55) - Not enough benefit (19) - Side effects (15)	32% (25–40%)	- Other (13) - Side effects (9) - Short life expectancy (8)	< 0.001
Tramadol 50 mg	71% (63–78%)	- Side effects (76) - Lower drug dose (8) - In reserve, no long-term therapy (8)	70% (63–77%)	- Side effects (69) - Lower drug dose (9) - In reserve, no long-term therapy (8)	0.71
Amlodipine 5 mg	44% (36–52%)	- No indication (22) - Side effects (22) - Not enough benefit (7) - Deprescribe the drug and evaluate the effect (7)	36% (28–44%)	- No indication (21) - Side effects (9) - Other (7)	0.011
Paracetamol 1 g	29% (22–37%)	- Lower drug dose (13) - In reserve, no long-term therapy (13) - Deprescribe the drug and evaluate the effect (6)	29% (22–36%)	- Lower drug dose (14) - In reserve, no long-term therapy (10) - Deprescribe the drug and evaluate the effect (6)	0.56
Enalapril 10 mg	24% (17–31%)	- No indication (15) - Side effects (5) - Lower drug dose (4)	19% (13–25%)	- No indication (13) - Lower drug dose (3) - Other (3)	0.033

¹P-value from McNemar’s test comparing percentages of GPs deprescribing each medication by CVD